MedRx Co., Ltd
Notice Regarding Monthly Exercise Status of the 35th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued by Third-Party Allotment
For the monthly exercise status, 14,770 stock acquisition rights were exercised in the target month, with an exercise ratio of 9.99%. Unexercised rights decreased to 41,395 rights (4,139,500 shares). Number of shares delivered in the target month: 1,477,000 shares. Unexercised stock acquisition rights at the end of the previous month were 56,165 rights (5,616,500 shares), and the exercise restriction ratio was 2.49%. The target month is September 2026.
Key Figures
- Number of shares delivered in the target month: 1,477,000 shares
- Number of stock acquisition rights exercised in the target month: 14,770 rights
- Total issued: 147,820 rights (of which exercised: 14,770 rights)
- Unexercised stock acquisition rights: End of month 41,395 rights (4,139,500 shares)
- Exercise restriction ratio: 2.49%
AI要約
Overview of Monthly Exercise Status of Stock Acquisition Rights
This report conveys the monthly exercise status for September 2026 of the 35th stock acquisition rights (with an exercise price adjustment clause) issued by third-party allotment. The number of shares delivered in the target month was 1,477,000 shares. During the month, 14,770 stock acquisition rights were exercised, representing 9.99% of the total issued. The number of unexercised stock acquisition rights at the end of the target month decreased to 41,395 rights (4,139,500 shares). Compliance with exercise restrictions was confirmed, with the exercise restriction ratio calculated at 2.49%.
Background and Points of Future Attention
This exercise reflects utilization of stock acquisition rights under specific conditions and may affect dilution and exercise-related risks. The decrease in unexercised rights compared to the end of the previous month may suggest increased exercise intent. There were no significant period-specific movements or market disturbances; additional information is expected to be provided in future monthly disclosures.
MedRx Co., Ltd
Company overview · Stock price · Financial data · All IR
